The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain: Are we comparing apples with oranges?

Thrombosis Research

Volumn 96, Issue 1, 1999, Pages 51-56

  Serebruany, Victor L ^a   Kereiakes, Dean J ^b   Dalesandro, Margaret R ^a   Gurbel, Paul A ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

Flow cytometry; Human; P selectin; Platelets

Indexed keywords

PADGEM PROTEIN;

ARTICLE; BLOOD; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EMERGENCY WARD; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLE; THORAX PAIN;

BIOLOGICAL MARKERS; BLOOD PLATELETS; CHEST PAIN; FLOW CYTOMETRY; HUMANS; P-SELECTIN; PROSPECTIVE STUDIES;

EID: 0032751873     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00063-8     Document Type: Article

References (20)

1. Davies M.J., Thomas A.C., Knapman P.A., Hangarter J.R. Intramyocardial platelet aggregation in patients with acute myocardial infarction suffering sudden ischemic cardiac death. Circulation. 73:1986;418-427.
2. Opie L.H. New concepts regarding events that lead to myocardial infarction. Cardiovasc Drugs Therap. 9(Suppl. 3):1995;479-487.
3. Carlos T.M., Harlan J.M. Leukocyte-endothelial cell adhesion molecules. Blood. 84:1994;2069-2101.
4. Lefer A.M., Weyrich A.S., Buerke M. Role of selectins, a new family of adhesion molecules, in ischaemia-reperfusion injury. Cardiovasc Res. 28:1994;289-294.
5. Weyrich A.S., Ma X.L., Lefer D.J., Albertine K.H., Lefer A.M. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest. 91:1993;2620-2629.
6. Ueyama T., Ikeda H., Haramaki N., Kuwano K., Imaizumi T. Effects of monoclonal antibody to P-selectin and analogue of sialyl Lewis X on cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. Circulation. 95:1997;1554-1559.
7. Ault K.A. Flow cytometric measurement of platelet function and reticulated platelets. Ann New York Acad Sci. 677:1993;293-308.
8. Faraday N., Goldschmidt-Clermont P., Dise K., Bray P.F. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med. 123:1994;728-740.
9. Katopodis J.N., Kolodny L., Jy W., Horstman L.L., De Marchena E.J., Tao J.G., Haynes D.H., Ahn Y.S. Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am J Hematol. 54:1997;95-101.
10. Langford E.J., Wainwright R.J., Martin J.F. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscl Thromb Vasc Biol. 16:1996;51-55.
11. Becker R.C., Tracy R.P., Bovill E.G., Mann K.G., Ault K. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. TIMI-III Thrombosis and Anticoagulation Group. Cor Artery Dis. 5:1994;339-345.
12. Bihour C., Durrieu-Jais C., Besse P., Nurden P., Nurden A.T. Flow cytometry reveals activated GP IIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coag Fibrinol. 6:1995;395-410.
13. Serebruany V.L., Gurbel P.A., Shustov A.R., Ohman E.M., Topol E.J. Heterogeneity of platelet aggregation and major surface receptor expression in patients presenting with acute myocardial infarction. Am Heart J. 136:1998;398-405.
14. Serebruany V.L., Gurbel P.A., Shustov A.R., Dalesandro M., Gumbs S.I., Grablutz B.S., Bahr R.D., Ohman E.M., Topol E.J., for the GUSTO-III Investigators Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction. Stroke. 29:1998;235-238.
15. Kereiakes D.J., Kleiman N.S., Ferguson J.J., Masud A.R., Broderick T.M., Abbottsmith C.W., Runyon J.P., Anderson L.C., Anders R.J., Dreiling R.J., Hantsbarger G.L., Bryzinski B., Topol E.J. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban. Results of a multicenter, placebo-controlled, randomized trial Circulation. 98:1998;1268-1278.
16. Ferguson J.J., Kereiakes D.J., Adgey A.A., Fox K.A., Hillegass W.B. Jr., Pfisterer M., Vassanelli C. Safe use of platelet GP IIb/IIIa inhibitors. Eur Heart J. 19(Suppl. D):1998;D40-D51.
17. Knight C.J., Panesar M., Wright C., Clarke D., Butowski P.S., Patel D., Patrineli A., Fox K., Goodall A.H. Altered platelet function detected by flow cytometry. Effects of coronary artery disease and age. Arterioscler Thromb Vasc Biol. 17:1997;2044-2053.
18. Stohlawetz P., Hergovich N., Stiegler G., Eichler H.G., Hocker P., Kapiotis S., Jilma B. Differential induction of P-selectin expression on platelets by two cell separators during platelet-pheresis and the effect of gender on the release of soluble P-selectin. Transfusion. 38:1998;24-30.
19. Broijersen A., Karpe F., Hamsten A., Goodall A.H., Hjemdahl P. Alimentary lipemia enhances the membrane expression of platelet P-selectin without affecting other markers of platelet activation. Atherosclerosis. 137:1998;107-113.
20. Michelson A.D., MacGregor H., Barnard M.R., Kestin A.S., Rohrer M.J., Valeri C.R. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost. 71:1994;633-640.